
Function Promoting Therapies LLC Profile last edited on: 3/12/2020
CAGE: 6KT27
UEI: WB7EPYZTRLF3
Business Identifier: Accurate diagnosis of male reproductive disorders Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 05
County: Middlesex
Congr. District: 05
County: Middlesex
Public Profile
Function Promoting Therapies, LLC, (FPT, LLC) and the firm's in-use (commercialization) arm of FPT, LLC, is organized around providing advanced technologies designed to improve accuracy in the diagnosis and rational management of testosterone replacement therapy for male reproductive disorders. Designated TruT Companion Diagnostics, the firm's approach is to achieve definitive diagnosis and institute rational management of androgen disorders. Based on the fundamental discovery of testosterone partitioning, FTC personnel has developed an accurate free testosterone determination method that with other key elements is enabling a framework for accurate determination of free testosterone values and to make progress towards an understanding of the basis of androgen disorders and other conditions.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $4,187,492 | |
Project Title: Novel Algorithm for Free Testosterone Determination |
Key People / Management
Shalender Bhasin
Dylan Bulseco -- Chief Commercialization Officer
Ravi Jasuja -- Chief Scientific Officer
Brian Lacroix -- Finance and Compliance
Brian Lawney -- Director of Computational Science
Sam Mawn-Mahlau -- Corporate counsel
Shantikumar Nair -- Principal Scientist
Mikhail Zakharov
Dylan Bulseco -- Chief Commercialization Officer
Ravi Jasuja -- Chief Scientific Officer
Brian Lacroix -- Finance and Compliance
Brian Lawney -- Director of Computational Science
Sam Mawn-Mahlau -- Corporate counsel
Shantikumar Nair -- Principal Scientist
Mikhail Zakharov
Company News
There are no news available.